ReviewInternational journal of nanomedicine2026
Advances in Nanotechnology for Lymphoma Treatment: Targeted Delivery, Immunomodulation, and TME-Responsive Therapy Strategies.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma is a heterogeneous malignant proliferative disease of lymphocytes, with characteristics of liquid tumor and solid tumor. With the emergence of targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T therapy, the treatment landscape for lymphoma has been transformed. However, these therapies also possess limitations such as short plasma circulation time, low bioavailability, the development of drug resistance, and dose-dependent toxicity. With the advancement of nanotechnology, nanotech-based targeted delivery systems enable tumor-specific targeting and reduce off-target toxicity. Nano-immunotherapeutic systems, such as nanobody-based CAR-T therapy and mRNA-LNP nanovaccines, address limitations like drug resistance and relapse caused by antigen escape, inducing long-term anti-tumor immunity. Furthermore, smart designs responsive to the tumor microenvironment (TME) can significantly enhance drug accumulation and release efficiency at the lesion site. Innovative nanotech-based therapies are progressively transitioning from the laboratory to the clinic. By designing targeted nanocarriers, nano-immunotherapies, and TME-responsive intelligent nanotherapeutic platforms, targeted delivery of anti-lymphoma drugs can be achieved, enhancing efficacy and reducing toxicity. Simultaneously, these platforms can integrate multiple therapeutic modalities (such as chemodynamic therapy, immunomodulation, and gene silencing) to achieve synergistic and enhanced anti-lymphoma effects, offering new paradigms for lymphoma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.